Top 10 Cefuroxime Sodium Injection Manufacturers Worldwide
Cefuroxime Sodium Injection is a sterile, injectable cephalosporin antibiotic used in clinical settings for infections caused by susceptible bacteria. Its quality depends on more than the active ingredient. Sterile production, validated processes, reliable testing, and clear product documentation all matter. Small details matter.
This article introduces ten manufacturers associated with Cefuroxime Sodium Injection across different regions. It is intended as a starting point for buyers, healthcare professionals, and researchers—not as a ranking or endorsement. Company portfolios and production sites can change, and a manufacturer’s presence in one market does not confirm availability or approval in another. Readers should verify current product information directly with the company and relevant health authorities.
When comparing manufacturers, consider whether they produce the finished injectable product or only supply an ingredient. Review publicly available information on manufacturing standards, quality systems, vial presentations, and distribution capabilities. A consistent supply chain is important, but so is transparent evidence of quality. There is no single checklist that fits every procurement need. This overview has limits, and publicly available details may not capture a facility’s full capabilities. For that reason, each company should be assessed independently against the requirements of the intended market and use.
Cefuroxime Sodium Injection: Composition, Uses, and Key Properties
Cefuroxime sodium injection is a sterile formulation of cefuroxime, a second-generation cephalosporin antibiotic. It works by disrupting bacterial cell-wall formation, preventing susceptible bacteria from growing normally. The active ingredient is supplied as cefuroxime sodium powder and reconstituted with a compatible diluent before use. The sodium salt supports the injectable formulation; it does not make the medicine suitable for every infection. That distinction matters.
Clinicians use it for certain bacterial infections when the likely or confirmed organisms are susceptible. Depending on the product and clinical plan, it may be given intravenously or intramuscularly. It does not treat viral illnesses such as colds. Culture results can help guide treatment, though they may not be available when care begins. Selection should also consider infection site, severity, local resistance patterns, and the patient’s history of allergy to cephalosporins or other beta-lactam antibiotics.
Preparation and dosing require care. Reconstitution instructions and storage limits can vary by product, so the approved product information should be checked rather than relying on memory. Kidney function may affect dose planning because cefuroxime is cleared largely through the kidneys. A practical detail can be missed: the prepared solution should be inspected for visible particles or unexpected discoloration. It is useful to be cautious, even when the powder looked normal.
Cefuroxime Sodium Injection: Composition and Dose Equivalence
A chemistry-based comparison of cefuroxime-equivalent doses and the corresponding calculated mass of cefuroxime sodium. This chart does not rank manufacturers.
Cefuroxime sodium is the sodium salt of cefuroxime. Calculations use molecular masses of approximately 446.37 g/mol for cefuroxime sodium and 424.39 g/mol for cefuroxime; values are rounded and exclude any excipients.
How Cefuroxime Sodium Injection Is Manufactured and Quality-Controlled
Manufacturing cefuroxime sodium injection begins with qualified cefuroxime sodium, checked for identity, potency, water content, and impurities. Each incoming lot is sampled under controlled conditions. Operators weigh the material in monitored rooms using calibrated balances and documented procedures. Small details matter. Exposure to moisture can affect a sensitive powder, so handling time, humidity, and container conditions are recorded.
Depending on the dosage form and validated process, the product may be prepared as a sterile solution or as sterile powder for aseptic filling. Solution preparation involves controlled dissolution and pH adjustment, followed by sterilizing filtration when suitable. Vials are washed, depyrogenated, and filled in qualified clean areas. Some presentations are freeze-dried, requiring careful control of the cycle. There is no universal recipe; formulation choices depend on stability data and process validation.
Quality control checks appearance, assay, related substances, particulate matter, sterility, endotoxins, and container-closure integrity. The pH is also tested after reconstitution. Batch records connect results with materials, equipment, and operators. Environmental monitoring tracks microorganisms and airborne particles during filling. A passing sterility test alone cannot prove perfect control; it examines only a sample. Trend reviews and investigations help identify recurring weaknesses. The process is precise, but never effortless.
Criteria for Evaluating Global Cefuroxime Sodium Injection Manufacturers
Selecting a cefuroxime sodium injection manufacturer takes more than comparing price and stated capacity. Review inspection histories, validated sterile-filling processes, and documented controls for sterility, endotoxins, and visible particles. Ask how suppliers qualify active ingredients and packaging components, manage deviations, and investigate failed batches. Request stability data for the marketed formulation and evidence that shipping conditions protect product quality. Small details matter.
Industry data adds context, not a shortcut. WHO’s 2023 Global Antimicrobial Resistance and Use Surveillance System report estimated that one in six laboratory-confirmed bacterial infections causing common infections in 2020 was resistant to antibiotic treatment. This supports careful stewardship and dependable quality, but does not rank individual manufacturers. ASHP reported 323 active drug shortages in the United States at the end of 2023, the highest year-end total since 2014; the figure covers medicines broadly, not cefuroxime alone. Evaluate continuity plans alongside quality: ask about backup production lines, raw-material risks, and realistic lead times. A clean audit is not the whole story. Compare recent batch-release records and corrective-action evidence where available, while recognizing that public disclosures can be incomplete. Numbers help.
Leading Cefuroxime Sodium Injection Manufacturers Worldwide
Leading cefuroxime sodium injection manufacturers worldwide distinguish themselves through consistent sterile production, careful testing, and dependable supply. Their work involves more than filling vials. Teams must control raw materials, maintain clean production areas, and verify each batch before release.
Look for evidence of robust quality systems and current, independently verifiable manufacturing credentials. Experienced producers use validated aseptic processes and test identity, strength, sterility, and particulate levels. They also document batch history and investigate deviations. Small process failures matter. A clear audit trail helps buyers assess how a manufacturer handles them.
Global suppliers may serve hospitals through different vial sizes, packaging formats, and distribution networks. Buyers should check whether product specifications, batch documents, and delivery plans fit their needs. Manufacturing capacity alone is not enough; reliability also depends on qualified suppliers and realistic lead times. No checklist is flawless. Even careful reviews can miss weak communication or changing capacity, so ongoing supplier assessment remains important.
Regulatory Standards and Global Supply-Chain Considerations
Regulatory Standards and Global Supply-Chain Considerations
Cefuroxime sodium injection requires more than a compliant active ingredient. Manufacturers must control sterility, endotoxins, visible particles, strength, and container-closure integrity. WHO’s GMP guidance for sterile pharmaceutical products emphasizes contamination control across facilities, equipment, and personnel. That matters at the filling line, where a poorly managed airlock can undermine an otherwise sound batch. Regulatory expectations also differ across markets, so buyers should check current national requirements and site approvals—not rely on a single certificate. Small details matter.
Supply-chain resilience deserves equal scrutiny. FDA’s 2019 report, Drug Shortages: Root Causes and Potential Solutions, found that 62% of shortages examined were associated with quality problems. The finding is not specific to cefuroxime, but it highlights why manufacturers should qualify multiple sources for critical materials and monitor supplier changes. For injectable products, review API traceability, vial and stopper specifications, testing records, and transport conditions. Ask for evidence of validated processes and recent inspection outcomes. Paperwork can look complete. Yet gaps may remain in change control or continuity planning. A practical supplier assessment should test these weak points, while recognizing that no audit can predict every disruption.





